Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Immunovia AB (publ)    IMMNOV   SE0006091997

SummaryNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Immunovia publ : Interim report, January-March 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/20/2017 | 08:31am CEST

"During the quarter we reported from a significant study that showed our ability to differentiate between SLE and other common autoimmune diseases. The very good results of the study, which indicated that SLE can be differentiated with 96% accuracy against a mix of healthy, rheumatoid arthritis, Sjögren's disease and vasculitis patient samples, give us a very strong reason to invest further in the autoimmune area."

"Also during the quarter we identified retrospective biobanks that contain relevant and well-documented blood samples from individuals who are afflicted with pancreatic cancer after being diagnosed with diabetes, and we will now conclude an agreement giving us access to these individuals so that we can perform the retrospective study we announced earlier."

"We are now planning the details of our market access program and preparing those marketing activities that will best create awareness among key decision-makers about the link between pancreatic cancer and diabetes and the possibilities that our test offer for improved survival."

Key indicators

Key indicators (SEK thousand1 Jan-311 Jan-31 March 2016Full year 2016
unless otherwise stated) March
2017
Net sales 28 0 177
Operating earnings -7 870 -2 435 -14 978
Earnings before tax -7 771 -2 406 -14 723
Net earnings -7 771 -2 406 -14 723
Earnings per share before -0,46 -0,17 -0,98
and after dilution
(SEK/share)
31 March31 March 2016  31 Dec. 2016
2017 
Equity ratio, % 97 97 98
No. of shares at the end of 16 804 14 291 216 16 804 059
the period 059
Average number of shares 16 804 14 291 216 14 985 688
before and after dilution 059

This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiary Immunovia Inc.

Outlook*
Immunovia is focused on fundamentally transforming diagnosis of complex forms of cancer and autoimmune diseases. The antibody-based platform, IMMray™, is the result of 15 years of research at CREATE Health - the Center for Translational Cancer Research at Lund University, Sweden. IMMray™ is a technology platform for the development of diagnostic tests and the company's

primary test. IMMray™ PanCan -d is the first test in the world for early diagnosis of pancreatic cancer.

·  It is planned to launch IMMray™ PanCan -d on the American and European markets with sales to out-of-pocket customers, to start when the accreditation and production upscaling have been completed, with revenues expected to begin in 2018. IMMray™ PanCan -d will address a market that in total is worth around SEK 30 billion.
·  Immunovia sees great potential in the development of tests for other unsolved problems in cancer and autoimmune diseases via its IMMray™ platform. The next focus area will be tests within SLE, based on the positive results announced in early 2017. 

For more information, please contact:

Mats Grahn  

Chief Executive Officer, CEO, Immunovia 

Tel.: +46-70-5320230 

Email: [email protected] 

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) 

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above. 

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company's Certified Adviser. For more information, please visit www.immunovia.com. 

###

http://news.cision.com/immunovia-ab/r/immunovia-interim-report--january-march-2017,c2242801

http://mb.cision.com/Main/13121/2242801/659719.pdf

(c) 2017 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOVIA AB (PUBL)
04/20 IMMUNOVIA PUBL : Interim report, January-March 2017
03/24 IMMUNOVIA PUBL : Ab kallar till årsstämma och publicerar årsredovisning för räke..
More news
Sector news : Medical Diagnostic & Testing Equipment
04/24DJPHILIPS : Net Profit Leaps; Backs Full Year Guidance
04/10DJCorrections & Amplifications -- WSJ
03/28DJPHILIPS : to Buy Australian pharmacy Sleep Services Firm
02/09 Infineon, Cree warn U.S. might block Wolfspeed deal
02/02 EU probes online sales in electronics, video games, hotels
More sector news : Medical Diagnostic & Testing Equipment
Advertisement
Financials ( SEK)
Sales 2016 0,02 M
EBIT 2016 -15,0 M
Net income 2016 -14,7 M
Finance 2016 259 095 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 -10 500 717x
EV / Sales 2017 0
Capitalization 1 827 M
More Financials
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mats Peter Egon Grahn Chief Executive Officer
Karl Arne Krister Borrebaeck Chairman
Lotta Blomgren Operations Director
Hans Liljenborg Chief Financial Officer
Lars Bertil Christer Wingren Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOVIA AB (PUBL)207
SARTORIUS AG12.87%6 652
SARTORIUS AG (PREFEREN..16.85%6 652
MYRIAD GENETICS, INC.9.96%1 248
DIRUI INDUSTRIAL CO LT..--.--%777
NH SPECIAL PURPOSE ACQ..--.--%408
More Results